Single-cell phenotyping for better drug discovery
- Institution
- Yale University, CT
- Principal investigator
- Elizabeth Hesper Rego
- Funding
- $461K
- Duration
- 2025–2027
Moonbase score
Still being scored
Abstract
Abstract Mycobacterium tuberculosis (Mtb) infects nearly 10 million people yearly and kills almost 1.5 million. Treating even drug-susceptible tuberculosis (TB) is difficult because subpopulations of bacteria, while not genetically resistant, can evade killing by antibiotics. To discover small molecule inhibitors for these tolerant subpopulations, we need to understand where they are located and what is their physiology. Directly identifying tolerant bacteria is impossible with conventional methods that rely on measurements from millions or billions of cells. Here, to overcome these limitations we have assembled a team with expertise in single-cell measurements, live-cell microscopy, and TB pathogenesis and metabolism. Leveraging these skills, we have succeeded in quantifying the growth and metabolism of individual mycobacteria in different subcellular environments. We propose to build upon these results and establish which subcellular environment is most associated with drug tolerance, and what carbon source is used by drug-tolerant M. tuberculosis. Then, we will design in vitro culture conditions mimicking this environment. These culture conditions will be used in future drug screening efforts designed to find small molecule inhibitors of drug tolerant mycobacteria.
LOADING MOONBASE SCORE
Questions for Yale University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Yale UniversityNot yet scored
Informing Drug Synergy: Investigating Mycobacterial Membrane Protein Structure and Function
Elizabeth Hesper Rego · $3.3M · 2025–2029
- NIH · Yale University72
Multimodal imaging of prodromal synaptic, circuit, and network-level dysfunction in a murine model of Alzheimer's disease
Zhengxin Cai · $834K · 2022–2027
- NIH · Yale University69
Neuron and microglia-specific proteomic signatures of ERK mediated mechanisms of Alzheimer's disease.
Srikant Rangaraju · $949K · 2023–2026